Bio-Techne Announces Early Access Program for Next-Generation Spatial Protein Proximity Detection
Bio-Techne (NASDAQ: TECH) has announced an Early Access Program for a new spatial protein proximity detection assay, built on RNAscope™ technology. The next-generation assay enables high-resolution visualization of protein interactions within intact tissues, providing functional insights into disease processes.
The technology addresses limitations of conventional methods by offering clear visual signals at subcellular resolution, compatible with the RNAscope™ Multiomic LS workflow on BOND RX. This advancement is particularly valuable for research in immune checkpoint dynamics, bispecific antibodies, and synaptic junction protein interactions.
The Early Access Program will be available to select institutions and researchers, with proof-of-concept data and case studies to be presented at the 2025 American Association for Cancer Research (AACR) annual meeting.
Bio-Techne (NASDAQ: TECH) ha annunciato un Programma di Accesso Anticipato per un nuovo saggio spaziale di rilevamento della prossimità proteica, basato sulla tecnologia RNAscope™. Il saggio di nuova generazione consente una visualizzazione ad alta risoluzione delle interazioni proteiche all'interno di tessuti intatti, offrendo approfondimenti funzionali sui processi patologici.
Questa tecnologia supera i limiti dei metodi convenzionali fornendo segnali visivi nitidi a risoluzione subcellulare, compatibile con il flusso di lavoro RNAscope™ Multiomic LS su BOND RX. Questo progresso è particolarmente utile per la ricerca sulla dinamica dei checkpoint immunitari, anticorpi bispecifici e interazioni proteiche nelle giunzioni sinaptiche.
Il Programma di Accesso Anticipato sarà disponibile per istituzioni e ricercatori selezionati, con dati di prova concettuale e casi di studio che saranno presentati al congresso annuale 2025 dell'American Association for Cancer Research (AACR).
Bio-Techne (NASDAQ: TECH) ha anunciado un Programa de Acceso Anticipado para un nuevo ensayo espacial de detección de proximidad proteica, basado en la tecnología RNAscope™. El ensayo de próxima generación permite la visualización de alta resolución de las interacciones proteicas dentro de tejidos intactos, proporcionando información funcional sobre los procesos de la enfermedad.
La tecnología supera las limitaciones de los métodos convencionales al ofrecer señales visuales claras a resolución subcelular, compatible con el flujo de trabajo RNAscope™ Multiomic LS en BOND RX. Este avance es especialmente valioso para la investigación en dinámicas de puntos de control inmunitarios, anticuerpos bispecíficos e interacciones de proteínas en uniones sinápticas.
El Programa de Acceso Anticipado estará disponible para instituciones e investigadores seleccionados, con datos de prueba de concepto y estudios de caso que se presentarán en la reunión anual 2025 de la American Association for Cancer Research (AACR).
Bio-Techne (NASDAQ: TECH)는 RNAscope™ 기술을 기반으로 한 새로운 공간 단백질 근접 검출 분석법에 대한 조기 접근 프로그램을 발표했습니다. 차세대 분석법은 온전한 조직 내 단백질 상호작용을 고해상도로 시각화하여 질병 과정에 대한 기능적 통찰을 제공합니다.
이 기술은 기존 방법의 한계를 극복하여 아세포 수준의 해상도로 명확한 시각 신호를 제공하며, BOND RX에서 RNAscope™ Multiomic LS 워크플로우와 호환됩니다. 이 발전은 면역 체크포인트 역학, 이중특이성 항체 및 시냅스 접합 단백질 상호작용 연구에 특히 유용합니다.
조기 접근 프로그램은 선정된 기관과 연구자들에게 제공되며, 개념 증명 데이터와 사례 연구는 2025년 미국 암 연구 협회(AACR) 연례 회의에서 발표될 예정입니다.
Bio-Techne (NASDAQ : TECH) a annoncé un Programme d'Accès Anticipé pour un nouveau test de détection de proximité protéique spatiale, basé sur la technologie RNAscope™. Ce test de nouvelle génération permet une visualisation haute résolution des interactions protéiques au sein de tissus intacts, offrant des insights fonctionnels sur les processus pathologiques.
La technologie répond aux limites des méthodes conventionnelles en offrant des signaux visuels nets à résolution subcellulaire, compatible avec le workflow RNAscope™ Multiomic LS sur BOND RX. Cette avancée est particulièrement précieuse pour la recherche sur la dynamique des points de contrôle immunitaires, les anticorps bispécifiques et les interactions protéiques aux jonctions synaptiques.
Le Programme d'Accès Anticipé sera disponible pour des institutions et chercheurs sélectionnés, avec des données de preuve de concept et des études de cas qui seront présentées lors de la réunion annuelle 2025 de l'American Association for Cancer Research (AACR).
Bio-Techne (NASDAQ: TECH) hat ein Early Access Programm für einen neuen räumlichen Protein-Nähe-Nachweis-Assay angekündigt, der auf der RNAscope™-Technologie basiert. Der Assay der nächsten Generation ermöglicht eine hochauflösende Visualisierung von Proteininteraktionen in intaktem Gewebe und liefert funktionelle Einblicke in Krankheitsprozesse.
Die Technologie überwindet die Einschränkungen herkömmlicher Methoden, indem sie klare visuelle Signale auf subzellulärer Auflösung bietet und mit dem RNAscope™ Multiomic LS Workflow auf BOND RX kompatibel ist. Dieser Fortschritt ist besonders wertvoll für die Forschung zu Immun-Checkpoint-Dynamiken, bispezifischen Antikörpern und Proteininteraktionen an synaptischen Verbindungen.
Das Early Access Programm wird ausgewählten Institutionen und Forschern zur Verfügung stehen, mit Proof-of-Concept-Daten und Fallstudien, die auf der Jahrestagung 2025 der American Association for Cancer Research (AACR) vorgestellt werden.
- Introduction of innovative spatial protein proximity detection technology expanding product portfolio
- Early Access Program launch demonstrates market readiness and commercial potential
- Technology addresses existing limitations in conventional research methods
- Early stage of commercialization with revenue impact in near term
- Success dependent on adoption by research institutions and validation of technology
Insights
Launch of advanced spatial assay strengthens Bio-Techne's technology leadership, but early access limits immediate financial impact.
Bio-Techne introduces an Early Access Program for a next-generation spatial protein proximity detection assay, leveraging its RNAscope™ platform. This innovation fills a significant gap in spatial biology by enabling visualization of protein interactions within their actual tissue context, not just protein presence. Most existing tools either lose spatial information or cannot directly show molecular relationships, so this solution could become essential for complex research domains such as immunology and neurobiology. Compatibility with the RNAscope™ Multiomic LS workflow supports integrated analyses, potentially driving adoption by top research institutions focused on disease mechanism elucidation and drug development, particularly in oncology. However, as the announcement is for limited early access—targeting select researchers and with broad rollout and commercial pricing not detailed—it does not immediately signal large-scale revenue generation or transformative financial impact. Proof-of-concept data are forthcoming, suggesting that commercial traction and clinical relevance will depend on future results and user feedback. For now, the development highlights strong R&D momentum and product pipeline depth but should be viewed as a strategic, not yet material, business event. Rating: neutral.
New assay enables high-resolution spatial visualization of protein interactions, unlocking functional insights within complex tissues
"This new protein proximity assay opens the door to seeing functional interactions between proteins and not merely their presence in a tissue," said Dr. Matt McManus, President of Bio-Techne's Diagnostics & Spatial Biology Segment. "It's a powerful step forward in understanding the dynamic interplay within tissues that drives biology and disease."
Conventional methods for studying molecular interactions in tissues that separately measure proteins and RNA risk losing spatial fidelity, while bulk proximity assays provide no localization data. Bio-Techne's proximity detection technology addresses these gaps with a clear visual signal at subcellular resolution, built to be compatible with the RNAscope™ Multiomic LS workflow on BOND RX. This capability is particularly valuable for research areas where context matters — such as assessing immune checkpoint dynamics, investigating bispecific antibodies and studying protein interactions at synaptic junctions.
The Early Access Program is available to select institutions and researchers interested in incorporating spatial protein proximity capabilities into their workflows. Proof-of-concept data and case studies will be shared at the 2025 American Association for Cancer Research (AACR) annual meeting, presented by Bio-Techne's scientific team.
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated approximately
About Bio-Techne Corporation (NASDAQ: TECH)
Contact: David Clair, Vice President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
View original content to download multimedia:https://www.prnewswire.com/news-releases/bio-techne-announces-early-access-program-for-next-generation-spatial-protein-proximity-detection-302436484.html
SOURCE Bio-Techne Corporation
FAQ
What is Bio-Techne's new spatial protein proximity detection technology?
How does TECH's new protein proximity assay differ from conventional methods?
What research applications will benefit from Bio-Techne's (TECH) new protein proximity assay?
When will Bio-Techne present data for their new spatial protein detection technology?
